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Background: The coronavirus disease 2019 (COVID-19) pandemic caused a halt to in-person ambulatory care. We
evaluated how the reduction in access to care affected HbA1c testing and patient HbA1c levels.
Methods: HbA1c data from 11 institutions were extracted to compare testing volume and the percentage of
abnormal results between a pre-pandemic period (January-June 2019, period 1) and a portion of the COVID-19
pandemic period (Jan-June 2020, period 2). HbA1c results greater than 6.4% were categorized as abnormal.
Results: HbA1C testing volumes decreased in March, April and May by 23, 61 and 40% relative to the corre
sponding months in 2019. The percentage of abnormal results increased in April, May and June (25, 23, 9%). On
average, we found that the frequency of abnormal results increased by 0.31% for every 1% decrease in testing
volume (p < 0.0005).
Conclusion: HbA1c testing volume for outpatients decreased by up to 70% during the early months of the
pandemic. The decrease in testing was associated with an increase in abnormal HbA1c results.

1. Introduction
The year 2020 brought with it the coronavirus disease 2019 (COVID19) pandemic that resulted in a global shutdown [1]. In March 2020,
after the World Health Organization (WHO) declared the pandemic,
many outpatient clinics were closed to in-person visits in an attempt to
slow the spread of disease. This resulted in many institutions scrambling
to get telehealth platforms in place to provide continuity of care to their
patients with chronic diseases. In Northern America (U.S. and Canada),
diabetes mellitus is amongst the most prevalent chronic diseases [2,3].

Primary care teams screen and make the initial diagnosis of diabetes
mellitus. Standard of care for people with diabetes mellitus includes
follow up visits every 3–6 months depending on the patient’s medication
regimen and the previous glycemic control [4]. In both scenarios,
measurement of HbA1c typically occurs at the time of these in person
visits and is essential for monitoring glycemic control.
With the shift to telehealth, many diabetes centers had to adjust their
chronic care flow. In Padua, Italy, there was a 47.7% decrease in
outpatient diabetes visits during shutdown [5]. With this reduction, they
saw that older patients with more comorbidities were less likely to be
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seen. Worryingly, the use of medications to reduce complications from
diabetes mellitus was decreased.

Table 2
Characteristics of participating institutions.
Institution

2. Methods
HbA1c data from 11 institutions was extracted to compare testing
volume and the percentage of abnormal results between a pre-pandemic
period (January-June 2019, period 1) and a portion of the COVID-19
pandemic period (Jan-June 2020, period 2). We determined the me
dian and the interquartile range (IQR) of the monthly volume of HbA1c
testing. We also determined the median and IQR of the percentage of
abnormal HbA1c results. HbA1c results greater than 6.4% were cate
gorized as abnormal. Point-of-care results and laboratory-based results
were aggregated.
We determined the impact of the pandemic by comparing the testing
volumes and the percentage of abnormal results for each month in
period 1 and period 2. We calculated the percent change in testing
volume, ΔV and the change in abnormal results, ΔA for each month at
each location (change was calculated relative to the corresponding
month in 2019). We also calculated the median percentage change in
volume, ΔVm and median percentage change in the number of abnormal
results, ΔAm over all locations. We calculated these statistics (ΔVm and
ΔAm ) for three cohorts: all patients, inpatients and outpatients.
Data from all sites were aggregated and five-point summaries were
calculated (minimum, 25th percentile, median, 75th percentile,
maximum) for each statistic by month for each patient cohort. The
monthly change was visualized by creating box plots of the percent
change in volume and abnormal results by month. We also tested for a
relationship between ΔV and ΔA using hierarchical regression with
location as a random effect and plotted the relationship between ΔV and
ΔA for each site (the slope and intercept were both modeled as random
effects).
We also compared the change in testing volume for HbA1c with the
change in total testing (exclusive of Covid-19 testing) at ARUP and at the
University of Utah hospital laboratory. ARUP is a national reference
laboratory that performs testing for hospitals across 50 states. Testing
volume for ARUP was selected as an indicator of testing nationally. The
study was limited to adults aged 18 to 70. We determined the sex and
age distribution of outpatients who received HbA1c testing.

University of Saskatchewan
University of Utah
University of CA, San Francisco
Los Angeles County, USC Medical Center
McMaster University
University of Iowa
Kaiser Permanente, Washington
Geisinger
Washington University, Saint Louis
University of Texas Southwestern Medical
Branch
University of Pennsylvania

Characteristics of Participating Institutions: Eleven institutions
participated in the study (Table 2). The institutions were dispersed
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43

Utah

1.00

ARUP

0.80

19–30

Percent
Abnormal

0.60

Relative Testing Volume, 2020/2019

Age Range

0.40

Male

1.20

Table 1
Demographics of Tested Outpatients at University of Utah Hospital Laboratory.
The cell entries represent the percentage in each category. For example, in
January 2019, 45% of those were tested were male and 13% of all patients (male
and female) were between 19 and 30 (inclusive).
Month

Monthly
Volume

geographically across the US (N = 9) and Canada (N = 2), the median
monthly volume of HbA1c testing in period 1 was 4968 (IQR: 3137 –
10929) for all patients, 826 for inpatients (IQR: 366-1181), and 3057
(IQR: 2256 – 9768) for outpatients. The median percentage of abnormal
HbA1c results was 38% (IQR: 32–44) for all patients, 41% (IQR: 36 – 46)
for inpatients, and 35% (IQR: 29 – 44) for outpatients.
Impact of Shutdown on Overall Testing at ARUP and the University
of Utah. The relative testing volume at ARUP and at the University of
Utah increased slightly in January and February but decreased in March
through May (Fig. 1). Similar results were seen for 25-OH vitamin D,
basic metabolic profile, and complete metabolic profile (Supplementary
Figs. 1 and 2).
Demographics of Tested Outpatients at the University of Utah: Fortytwo percent of the tested population was male. Ages were evenly
distributed and demonstrated little variation by year (Table 1).
Impact of Shutdown on HbA1c Testing Volume and Abnormal Re
sults. Across all participating institutions, the volume of HbA1c testing
for all patients increased by about 16% in 2020 relative to 2019 over the
months of January and February (Fig. 2, Supplemental Table 1). Testing
volumes decreased in March, April and May by 23, 61 and 40% relative
to the corresponding months in 2019 but increased by 2% in June. There
was little change in the frequency of abnormal results over the first three
months of 2020 (ΔAm = 2, − 1 and − 4%); however, the frequency of
abnormal tests increased by about 19% in April and May, and returned
to baseline in June (ΔAm = 2%).
The volume of HbA1c testing for inpatients increased by about 7% in

3. Results

Year

Baseline HbA1c Testing (2019
average)

1

2

3

4

5

6

Month

Fig. 1. Change in Relative Testing Volume by Month. The figure shows the
ratio of total testing (2020/2019) for ARUP and the University of Utah hospital
laboratory. Covid testing was excluded.
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All patients

1.0
0.5
0.0

Percentage change

−0.5

Inpatients

1.0
0.5

Abnormal

0.0

Volume

−0.5

Outpatients

1.0
0.5
0.0
−0.5
Jan

Feb

Mar

Month

Apr

May

Jun

Fig. 2. Change in the Relative Testing Volume and Relative Percentage of Abnormal HbA1c Results by Month. Relative change was measured as 2020 results
relative to 2019. HbA1c results greater than 6.4% were categorized as abnormal. Each month represents results from 11 sites. The white line in the box indicates the
median and the length of the box indicates the interquartile range. Dots indicate outliers. Numerical values corresponding to the figure are detailed in supple
mental Table 1.

January and February, decreased by approximately 17% during March
and April, and recovered to 2019 levels in May and June (ΔVm = -5 and
7%) (Fig. 2). The percentage of abnormal results showed little change in
2020 relative to 2019. The percent change of abnormal results ranged
from a decrease of 2% to an increase of 5%.
The volume of HbA1c testing for outpatients increased by 14 and
23% in January and February, decreased 28, 70 and 50% March to May,
and recovered to 2019 levels in June. The percentage of abnormal re
sults was similar to 2019 in January to March of 2020 (ΔAm = -1, − 5,
and 2) but increased in April, May and June (ΔAm = 25, 24, 9%)
We tested for a relationship between the percent change in testing
volume (ΔV) and the percent change in abnormal HbA1c results (ΔA)
among outpatients Ten of 11 locations showed a negative relationship
between testing volume and abnormal HbA1c result frequency (Fig. 3).
The relationship varied by site. For example, at one site there was a
0.85% decrease in abnormal results for every one percent increase in
testing volume. At another site, there was a 0.09% increase in abnormal
results for every one percent increase in testing volume. On average, we
found that the ΔA decreased by 0.31% for every 1% increase in ΔV (p <
0.0005). That is, decreases in testing volume were associated with an
increase in the frequency of abnormal results.

4. Discussion
The COVID-19 pandemic brought with it the harsh reality that
outpatient care for people with diabetes mellitus was not equipped for
remote monitoring. The data show that testing for the quintessential
‘standard of care’ measurement for glycemic control (HbA1c) was
decreased up to 70% during the height of shutdown (April 2020) sug
gesting that many patients went without formal assessment of glycemic
control for at least 3–4 months. This could have been prevented.
The current recommendation is to monitor the HbA1c every 3
months in patients with diabetes mellitus (depending on prior glycemic
control), annual screening in adults with prediabetes and screening at
least every 3 years in adults over the age of 65 years and adults who are
overweight/obese with at least one risk factor [6]. This is a large group
and encompasses a significant portion of people receiving primary care
and endocrinology outpatient clinics. The recommendation of moni
toring HbA1c quarterly is based on prior data showing that decreased
testing is associated with a 1.5% increase in HbA1c (i.e., worse glycemic
control), whereas frequent monitoring was associated with a 3.8%
decrease in HbA1c (i.e. improved glycemic control) [7]. Given the
prolonged trajectory of the pandemic, continued lack of testing may
result in worsening of glycemic control which can eventually result in
worsened health outcomes in those with diabetes mellitus [8], and in a
150
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50
0
−50

Percent Change in Abnormal Results

100

This study has several limitations. The study only covered a single
test. A survey of a broader range of tests could have provided more
insight into the impact of Covid-19; however, for clarity and for logis
tical reasons, we decided to limit the study to HbA1c. We selected
HbA1c because it is an important test that affects a large population and
has a widely accepted reference limit for abnormal results. We found
that the decrease in HbA1c testing during the early phase of the
pandemic was consistent with the pattern of total testing performed at a
national reference laboratory and with the pattern of testing at a uni
versity hospital laboratory. Thus, the decrease in laboratory testing was
widespread and was not isolated to HbA1c.
We did not collect data on subpopulations such as type I or type II
diabetes, pediatric patients, or explore the underlying reason for the
HbA1c test (e.g., diagnosis, annual exam, follow-up). While these data
would provide additional insight, our objective was to identify broad
patterns across multiple institutions. Collecting such data could be
possible in a single institution but would have been challenging to
collect across multiple institutions. We did not include the pediatric
population which could account for a large portion of tests. It is possible
that results differ for the pediatric population. Despite this, we believe
our results show the impact of reduced access to testing on an important
population.
The objective of the study was to identify broad patterns in testing
volume and in abnormal results. Consequently, we did not perform a
longitudinal analysis by patient to look for detailed patterns in testing.
We assumed that testing would be approximately uniformly distributed
over time and, for that reason, it was sufficient to compare aggregate
results beginning in Jan 2019.
The most important strength of this study is the broad sampling
across the United States and Canada. In addition, the relationship be
tween the testing volume and the frequency of abnormal results was
consistent in 91% of centers (10/11). The data reflect sampling from
people who accessed care and are therefore at risk to selection and/or
convenience bias. The parameters measured were volume of HbA1c
testing and therefore further conclusions beyond those mentioned are
unable to be drawn. Underlying characteristics of the individuals who
were tested and why they did get tested are unknown. In particular, we
were unable to distinguish between tests performed for screening,
diagnosis and monitoring.
The COVID-19 pandemic brought with it a major disruption to
outpatient care. This highlighted a significant deficit in glycemic
monitoring by traditional measures (HbA1c). It also brought to light the
benefits of telehealth. As we look ahead, outpatient diabetes care teams
should shift gears and focus on education and implementation of the
available technologies to perform effective, complete virtual care. Tel
ehealth can fill the gap in traditional care models and prevent disruption
to standard of care whenever the next pandemic strikes.

−100

−50

0

50

Percent Change in Testing Volume

Fig. 3. Relationship between the Relative Testing Volume and Relative
Percentage of Abnormal Results (2020 relative to 2019) for Outpatients by
Location. Each line shows the relationship between the percentage change in
abnormal results, ΔA, and the percentage change in HbA1c testing volume, ΔV,
for one location.

delay of making a new diagnosis of diabetes mellitus which can lead to a
higher incidence of diabetes mellitus in the future due to lack of early
intervention measures [9]. Indeed, the decreased testing was not only
seen in the care of diabetes mellitus but across all outpatient specialties
[10,11].
While the outpatient HbA1c testing volume was significantly lower,
the inpatient HbA1c testing volume did not change significantly. Other
authors noted decreased acute surgical [12] and cardiac complaints
[13], similar hip fracture frequencies [14] and increased adult psychi
atric admissions [15]. In one of the largest cohorts from New York
focusing on the comorbidities of hospitalized patients with COVID-19,
diabetes mellitus was the third most common comorbidity (33.8%)
after hypertension (56.6%) and obesity (41.7%). It is likely that the lack
of change of inpatient HbA1c testing during the shutdown months were
due to increased inpatient management of people with diabetes mellitus.
Once the switch to telehealth was made, the outpatient volumes
increased and then a delayed increase in HbA1c testing volume was seen
in May with a return to normal in June 2020. Medical video commu
nication has been used since 1959 [16] yet, by January 2020, it still had
not been widely utilized by the medical community. Multiple studies
have shown improved glycemic control with telehealth [17-19]. Reim
bursement, however, has historically prevented its use and thus created
a barrier for most institutions across the country [20]. The pandemic
brought with it a lift to these barriers, allowing telehealth to take its
rightful place in diabetes management. In patients with a diagnosis of
diabetes mellitus, cloud-based platforms for remote monitoring of
glucose meters, continuous glucose monitors and insulin pumps are
more easily accessible than in the past. In fact, the information from
these devices can be more valuable than the actual HbA1c because they
reveal continuous results rather than a longitudinal average. The
Australian government recognized this and moved swiftly to ensure
people with diabetes mellitus had access to these technologies during
the pandemic [21]. The use of home HbA1c monitoring [22] and urine
albumin testing [23] are also available. Mobile phlebotomy units can be
accessed for other necessary lab draws. Data sharing between electronic
medical record systems and clinical laboratories would be the final step
to close the loop ensuring a complete virtual visit. If these systems are in
place, access to care would be available for much of the population.
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